77278-93-4

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(TERT-BUTOXYCARBONYL)-4-((2-PYRIDYL)METHYL)PIPERAZINE is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex molecular structures that can have therapeutic effects.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, 1-(TERT-BUTOXYCARBONYL)-4-((2-PYRIDYL)METHYL)PIPERAZINE is used as a building block for creating new organic compounds, taking advantage of its reactive functional groups to form a variety of chemical entities.
Used in Medicinal Chemistry:
1-(TERT-BUTOXYCARBONYL)-4-((2-PYRIDYL)METHYL)PIPERAZINE is utilized as a key component in medicinal chemistry, where its structure can be optimized to develop new drugs with specific therapeutic targets.
Used in Drug Development:
In drug development, 1-(TERT-BUTOXYCARBONYL)-4-((2-PYRIDYL)METHYL)PIPERAZINE is used as a starting material to create potential drug candidates, leveraging its unique structural features to design molecules with desired pharmacological properties.

InChI:InChI=1/C15H23N3O2/c1-15(2,3)20-14(19)18-10-8-17(9-11-18)12-13-6-4-5-7-16-13/h4-7H,8-12H2,1-3H3

Upstream product

• 6959-47-3 2-chloromethylpyridine hydrochloride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 55401-97-3 2-(Bromomethyl)pyridine 
• 1121-60-4 pyridine-2-carbaldehyde 
• 24424-99-5 di-tert-butyl dicarbonate 
• 55579-01-6 1-(pyridine-2-ylmethyl)piperazine 

Downstream Products

• 1818389-84-2 N-(2-(4-(pyridin-2-ylmethyl)piperazin-1-yl)-5-trifluoromethyl)phenyl-5-(pyridin-4-yl)furan-2-carboxamide 
• 149692-12-6 1-(3-((N-phenoxycarbonyl)amino)-3-phenylpropanoyl)-4-((2-methyl-3-pyridyl)cyanomethyl)piperazine 
• 149691-82-7 1-(3-(N-(tert-butoxycarbonyl)amino)-3-phenylpropanoyl)-4-((2-methyl-3-pyridyl)cyanomethyl)piperazine 

Relevant academic research and scientific papers

PIPERAZINE DERIVATIVES FOR TREATING DISORDERS

Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.

NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and methods of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor. (I).

Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor

A series of 3-aryl-5-acylpiperazinyl-pyrazoles (e.g., 3a-b) initially identified through a high-throughput screening campaign using the aequorin Ca2+ bioluminescence assay as novel, potent small molecule antagonists of the G protein-coupled hum

Synthesis and Structure-Activity Relationships of 1-Acyl-4-(2-methyl-3-pyridyl)cyanomethyl)piperazines as PAF Antagonists

A second generation of (cyanomethyl)piperazines, 1-acyl-4-((2-methyl-3-pyridyl)cyanomethyl)piperazines, with increased oral activity was prepared and evaluated in vitro in PAF-induced platelet aggregation assay (PAG) and in vivo in a PAF-induced hypotension test in normotensive rats (HYP).Oral activity was ascertained through a PAF-induced mortality test in mice (MOR).Attachment of a methyl group at position 2 of our earlier pyridine derivatives resulted in an improvement of 1 order of magnitude or greater in the ID50 of the oral test.Three different types of acylsubstituents of similar potency emerge from this work: N-(diphenylmethylamino)acetyl, 3-substituted 3-hydroxy-3-phenylpropionyl, and N-substituted 3-amino-3-phenylpropionyl groups.The most interesting compounds, 26 (UR-12460, PAG IC50 = 0.040 μM, HYP, ID50 = 0.021 mg/kg iv, MOR, ID50 = 0.30 mg/kg po) and 58 (UR-12519, PAG IC50 = 0.041 μM, HYP, ID50 = 0.015 mg/kg iv, MOR, ID50 = 0.044 mg/kg po), compare favorably with WEB-2086.Compounds 26 and 58 were also tested in active anaphylactic shock (AAS) and endotoxin-induced mortality (EIM) tests.On the basis of these data, compounds 26 and 58 have been selected for further pharmacological development.

(2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists

The present invention relates to new (2-alkyl-3-pyridyl) methylpiperazine derivatives of general formula I: wherein R1, R2 and Z are as defined in Claim 1. The invention also relates to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent, orally active PAF antagonists and, consequently, they are useful in the treatment of the diseases in which this substance is involved.